SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy ($SWEAT) is trending as the community speculates on its long-term potential, driven by recent token burns and its expanding utility as a multi-chain 'universal gas token.' Many users are actively discussing the crypto's 'move-to-earn' incentives and new ecosystem features, expressing strong optimism for its future growth despite current price levels.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is sharply lower after its mixed quarterly report showed strong revenue growth and user acquisition but also a net loss driven by increased credit loss provisions and a cautious near-term forecast. The community is debating the long-term viability of the buy now, pay later model amidst concerns over credit risk and the company's path to profitability.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL Inc. is trending due to a steep stock decline after its Galleri cancer test missed a primary statistical endpoint in a UK trial. This has sparked a divided community discussion, with some viewing the sell-off as an overreaction given positive underlying detection data and strong financials, while others emphasize the trial's miss and broader biotech sector risks.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending amid reactions to a new public stock offering and a contingent royalty funding agreement, fueling community debate about significant shareholder dilution versus securing critical capital for its lead prostate cancer candidate's potential commercialization and to strengthen its financial runway.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG CRYPTO is trending as its dedicated community celebrates its 1-year anniversary, rallying around its unique "infinite money glitch" model that automatically rewards holders with Solana and continues to roll out new features and liquidity pools.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is gaining attention following news of institutional interest through potential Grayscale and Bitwise ETF filings, a significant token inflation reduction, and its collaboration with NVIDIA for AI development. The community is actively accumulating, viewing its advanced AI integration and growing 'Intents' cross-chain utility as strong catalysts for a substantial rally.

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Tandem Diabetes Care Inc

Tandem Diabetes Care is trending due to a recent earnings miss and a voluntary medical device correction for its t:slim X2 insulin pumps, sparking a polarized community debate between those buying the dip, citing strategic partnerships and new product launches, and bears predicting further declines amidst competitive pressures.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending due to its transformative all-stock merger with Valaris, creating a dominant offshore drilling powerhouse with an expanded fleet and substantial backlog. Community discussion, despite initial earnings reports, is focused on the adjusted positive performance, significant debt reduction efforts, and the strategic advantages of the acquisition in a resurgent energy market, with many anticipating a short squeeze.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community eagerly anticipates the imminent resubmission of its Biologics License Application for Deramiocel, a Duchenne muscular dystrophy treatment, driving optimism for a significant short squeeze. Investors are closely watching for updates on the company's StealthX vaccine platform and broader FDA regulatory consistency, viewing CAPR as a promising, undervalued biotech in the rare disease space.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending as community discussion centers on its unique potential to significantly increase oil production and exports from Venezuela following recent U.S. policy shifts, which, combined with broader geopolitical tensions driving oil prices higher, is fueling optimism.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Selling: Solid Biosciences (NASDAQ:SLDB) CEO Sells 16,644 Shares of Stock

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CEO Alexander Cumbo sold 16,644 shares of Solid Biosciences stock in a transaction that occurred on Wednesday, February 18th. The stock was sold...

Insider Selling: Solid Biosciences (NASDAQ:SLDB) Director Sells 2,658 Shares of Stock

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) Director Ilan Ganot sold 2,658 shares of Solid Biosciences stock in a transaction on Wednesday, February 18th. The stock was sold at an average...

Paul Herzich Sells 3,616 Shares of Solid Biosciences (NASDAQ:SLDB) Stock

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CTO Paul Herzich sold 3,616 shares of the firm's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an...

Solid Biosciences (NASDAQ:SLDB) Insider Jessie Hanrahan Sells 4,134 Shares

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) insider Jessie Hanrahan sold 4,134 shares of Solid Biosciences stock in a transaction that occurred on Wednesday, February 18th. The stock was...

David Howton Sells 7,469 Shares of Solid Biosciences (NASDAQ:SLDB) Stock

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) COO David Howton sold 7,469 shares of Solid Biosciences stock in a transaction dated Wednesday, February 18th. The stock was sold at an average...

Insider Selling: Solid Biosciences (NASDAQ:SLDB) CEO Sells $96,868.08 in Stock

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CEO Alexander Cumbo sold 16,644 shares of the company's stock in a transaction on Wednesday, February 18th. The stock was sold at an average...

Solid Biosciences (NASDAQ:SLDB) CFO Kevin Tan Sells 5,404 Shares

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CFO Kevin Tan sold 5,404 shares of the firm's stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of...

Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreich's Ataxia Update

Solid Biosciences (NASDAQ:SLDB) used a presentation at the 2026 Emerging Outlook Biotech Summit to outline its gene therapy-focused pipeline and discuss recent regulatory interactions around its lead...

Needham & Company LLC Reaffirms Buy Rating for Solid Biosciences (NASDAQ:SLDB)

Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price objective on shares of Solid Biosciences in a report on Monday...

Solid Biosciences (NASDAQ:SLDB) CEO Sells $314,999.72 in Stock

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CEO Alexander Cumbo sold 48,913 shares of Solid Biosciences stock in a transaction on Wednesday, February 4th. The shares were sold at an...

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

SLDB
Solid Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLDB News

SLDBSolid Biosciences Inc